Refractory Small Lymphocytic Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +9 more
2022-04-07
Apr 7, 2022
N
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Active, not recruiting
  • Recurrent B-Cell Prolymphocytic Leukemia
  • +5 more
  • Palo Alto, California
  • +2 more
2022-04-05
Apr 5, 2022
N
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
Active, not recruiting
  • Ann Arbor Stage III Small Lymphocytic Lymphoma
  • +7 more
  • Washington, District of Columbia
  • +1 more
2022-04-05
Apr 5, 2022
F
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022
M
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-15
Mar 15, 2022
M
Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic
2022-03-25
Mar 25, 2022
M
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +4 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
2022-03-22
Mar 22, 2022
M
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
Not yet recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-03
Mar 3, 2022
F
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Recruiting
  • Acute Leukemia
  • +18 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
N
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Suspended
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +25 more
  • Birmingham, Alabama
  • +23 more
2022-03-05
Mar 5, 2022
M
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation - 2022
Completed
  • Loss of Chromosome 17p
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-04
Mar 4, 2022
C
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CpG-STAT3 siRNA CAS3/SS3
  • Radiation Therapy
  • Duarte, California
    City of Hope Medical Center
2022-02-28
Feb 28, 2022
F
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia - 2021
Completed
  • CD19-Positive Neoplastic Cells Present
  • +12 more
  • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-08
Feb 8, 2022
M
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-10
Feb 10, 2022
M
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Not yet recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +6 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2022-02-18
Feb 18, 2022
O
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +58 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
2022-02-16
Feb 16, 2022
M
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Active, not recruiting
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-09
Feb 9, 2022
F
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-01-24
Jan 24, 2022
J
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Recruiting
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-12-17
Dec 17, 2021
V
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL - 2021
Withdrawn
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Dose combination 1-1
  • +5 more
  • (no location specified)
2021-11-01
Nov 1, 2021
N
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma - 2021
Completed
Has Results
  • Recurrent Follicular Lymphoma
  • +10 more
  • Denver, Colorado
  • +10 more
2021-09-04
Sep 4, 2021
S
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL - 2021
Completed
Has Results
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duarte, California
  • +1 more
2021-09-01
Sep 1, 2021
M
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • Scottsdale, Arizona
  • +1 more
2021-08-10
Aug 10, 2021
C
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duarte, California
  • +2 more
2021-08-13
Aug 13, 2021
J
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Recruiting
  • CD19 Positive
  • +13 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
2021-08-10
Aug 10, 2021